<DOC>
	<DOCNO>NCT01562730</DOCNO>
	<brief_summary>Study evaluate new technique MyoVista™ iECG sensitivity ability predict myocardial disease , compare iECG result Computed Tomography Coronary Angiography finding</brief_summary>
	<brief_title>Myovista iECG Detecting Ischemic Heart Disease : Comparison With Computed Tomography Coronary Angiography</brief_title>
	<detailed_description>Clinical need Non-invasive identification patient coronary artery disease use single , highly reliable technique challenge . Computed tomography coronary angiography ( CTCA ) emerge patient-friendly , accurate diagnostic tool . Compared invasive coronary angiography , sensitivity specificity CTCA detect significant coronary stenosis report high 90 % . Moreover , CTCA allow detection nonobstructive coronary plaque ( CAPs ) . However , advantage CTCA frequently reduce significantly high radiation exposure . New MyoVista™ iECG technology The MyoVista™ ( Heart Test Laboratories Inc. , Colleyville , TX , USA ) novel electrocardiographic device . The clinical set MyoVista™ identical traditional 12-lead ECG acquire process signal information way permit much great resolution electrical activity associate myocardium ( iECG ) . This technology property Heart Test Laboratories allow analysis entire myocardium provide visual indicator waveforms clinical evaluation . Study rationale MyoVista™ technology far validate cohort Asian patient undergo clinically-indicated coronary angiography . These study show high positive negative predictive value identification CAD . In addition , preliminary study perform USA suggest potential incremental value iECG routine surface ECG screen tool detection subclinical LV dysfunction latent cardiovascular risk . The aim prospective control evaluation ass 1. sensitivity , specificity , predictive value MyoVista™ iECG consecutive individual without history cardiovascular disease undergo clinically indicate Computed Tomography Coronary Angiography ( CTCA ) detect Coronary Artery Plaque ( CAP ) and/or Coronary Artery Disease ( CAD ) ( Group 1 ) ; 2. sensitivity , specificity , predictive value MyoVista™ iECG consecutive individual history cardiovascular disease undergo clinically indicate CTCA detect extent CAP CAD ( Group 2 ) ; 3. whether MyoVista™ iECG abnormality well predictor traditional risk factor prevalence CAP individual without history cardiovascular disease .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<criteria>chest pain , shortness breath , syncope equivocal stress test include exercise ECG , myocardial perfusion imaging , stress echocardiography unable exclude significant coronary artery disease . All patient provide write oral consent CTCA . Patient agree participate sign inform consent usually renal insufficiency ( serum creatinine &gt; 120 mol/l ) , contraindication administration iodinate contrast , pregnancy , acute coronary syndrome , ventricular and/or supraventricular arrhythmia .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Myocardial Ischemia</keyword>
	<keyword>Coronary Disease</keyword>
	<keyword>Heart Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Arteriosclerosis</keyword>
	<keyword>Arterial Occlusive Diseases</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>iECG</keyword>
	<keyword>12 lead ECG</keyword>
</DOC>